Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 8/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27257479 | 1.00 | SLC6A9 (0.37) | SLC6A9EPHX2SLC1A5PMP22KIF11 | |
| SCHEMBL32670641 | 1.00 | SLC6A9 (0.37) | SLC6A9EPHX2SLC1A5PMP22KIF11 | |
| SCHEMBL27257486 | 1.00 | SLC6A9 (0.37) | SLC6A9EPHX2SLC1A5PMP22KIF11 | |
| SCHEMBL27259706 | 0.89 | SLC6A9 (0.38) | SLC6A9EPHX2SLC1A5KIF11 | |
| SCHEMBL27257481 | 0.85 | POLB (0.40) | EPHX2SLC1A5KIF11 | |
| SCHEMBL27257584 | 0.84 | PMP22 (0.40) | PMP22KIF11 | |
| SCHEMBL27254861 | 0.84 | PMP22 (0.40) | PMP22KIF11 | |
| SCHEMBL30788826 | 0.79 | PPARA (0.39) | SLC6A9 | |
| SCHEMBL32670628 | 0.76 | SLC6A9 (0.35) | SLC6A9 | |
| SCHEMBL32670541 | 0.76 | SLC6A9 (0.35) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4565228-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024030960-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | SLC6A9 1336/4885EPHX2 1957/4885SLC1A5 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.